Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intercell, a biotech-vaccine company, has reported revenues of EUR32.2m for the fourth quarter ended December 31, 2009, an increase of 5.6%, compared to EUR30.48m for the same period in 2008. Operating income was EUR7.93m, compared to EUR6.24m for the prior year period.
Subscribe to our email newsletter
Intercell has posted a net income of EUR7.5m, compared to EUR30.96m for the comparable period in 2008.
For the full year ended December 31, 2009, the company has posted a net loss of EUR8.37m, compared to EUR17.17m for the year ago period. Revenues were EUR61.68m for the 12 months, an increase of 10.6%, compared to EUR55.76m for the year ago period. Operating loss was E30.46m, compared to EUR13.82m for the year ago period.
The company has said that according to current plans, product sales are expected to increase as of Q2 2010. Product supplies to marketing and distribution partners for the main travel season are expected to partially shift from Q1 to Q2 2010 due to lot release timing for European markets.